Drug Discovery


Drug Discovery Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018

Date Published: Mar 12 2014

OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018

Summary

$5,995.00
Oncology Development Strategies - Considerable commercial potential but specific needs must be addressed

Oncology Development Strategies - Considerable commercial potential but specific needs must be addressed

Date Published: Jan 15 2013

Oncology Development Strategies - Considerable commercial potential but specific needs must be addressed

Summary

$3,900.00
Companion Diagnostics - Streamlining drug development and advancing personalized medicine

Companion Diagnostics - Streamlining drug development and advancing personalized medicine

Date Published: Apr 15 2013

Companion Diagnostics - Streamlining drug development and advancing personalized medicine

Summary

Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around for many years, it is only with the advent of companion diagnostics that personalized healthcare has started to gain ground. Companion diagnostics can be used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize risk

$3,900.00
Pathways to Efficient Drug Development - Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity

Pathways to Efficient Drug Development - Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity

Date Published: Sep 30 2012
$3,500.00
Market Research - Biopharmaceutical Manufacturing in India, China and South Korea 2012

Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth

Date Published: Oct 1 2012
$3,500.00
Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation

Date Published: Nov 9 2012
$3,500.00
Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes

Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes

Date Published: Nov 9 2012
$3,500.00
Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share

Date Published: Jan 22 2013
$3,500.00
Cosmeceuticals Market to 2018 - Technological Advances and Consumer Awareness Boost Commercial Potential for Innovative and Premium-Priced Products

Cosmeceuticals Market to 2018 - Technological Advances and Consumer Awareness Boost Commercial Potential for Innovative and Premium-Priced Products

Date Published: Jan 22 2013
$3,500.00
Arthritis Therapeutics Market to 2018

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Date Published: May 18 2012
GBI Research’s new report, “Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications”, provides an expert insight into the global arthritis market and market forecast until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
$3,500.00
Patient Perspectives A Report

Patient Perspectives - Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge

Date Published: May 18 2012

Patient Perspectives - Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge

 

Summary

 
$3,500.00
Biomarkers in Drug Discovery

Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly

Date Published: Oct 3 2011

Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly

 

Summary

 
$3,500.00
Re-evaluating Pharmaceutical Pipelines - Emerging Markets

Re-evaluating Pharmaceutical Pipelines - Emerging Markets, Biologics and Orphan Drugs to Shape Future Decision Making

Date Published: Jun 12 2012
Re-evaluating Pharmaceutical Pipelines - Emerging Markets, Biologics and Orphan Drugs to Shape Future Decision Making
 
Summary
 
$3,500.00
e-Clinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies

e-Clinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies

Date Published: Jul 31 2012
e-Clinical Trial Solutions Market to 2018 Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies report provides key data and analysis of the major factors affecting the market for eClinical trial solutions in the pharmaceuticals industry. The report also analyzes the opportunities and threats in the eClinical trial solutions market, and the key market drivers and barriers to the adoption of eClinical trial solutions in the industry.
 
$3,500.00
Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets

Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets

Date Published: Jul 31 2012
$3,500.00
Biological and biosimilars drug market in Poland 2013

Biological and biosimilars drug market in Poland 2013

Date Published: Aug 1 2013

Examine the future of biologics in the Polish pharma market.
Report surveys biologic and biosimilar drugs, epidemiology and growth potential 2013- 2015.

$2,660.00
Therapeutic Class Overview : Psoriasis – Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm

Therapeutic Class Overview : Psoriasis – Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm

Date Published: Feb 24 2014
$2,500.00
Outlook 2012 - Rising Stars - Innovators Deliver but Rewards Not Guranteed - Market Research Report

Outlook 2012 - Rising Stars - Innovators Deliver but Rewards Not Guranteed

Date Published: Dec 23 2011

Innovation and improvements through novel technology platforms will continue to flow from the backyards of small research focused companies (Rising stars, RS) but commercial success of launched products is not assured despite patents. Best returns on investment in RS companies came from those in early or mid stage of products development (Pharmasset, Curis, Halozyme, etc) than those with registered/launched products (HGSI, INCY, ALTH, SVNT, AMAG etc). "Outsourcing" will speed up even within geographies as companies are trying to maintain a "Trim Line".

$2,000.00
Alzheimer's Disease - Is there Merit in Pursuing "Amyloid-ism" or "Tau-ism"? - Market Research Report

Alzheimer's Disease - Is there Merit in Pursuing "Amyloid-ism" or "Tau-ism"?

Date Published: Jan 9 2012

There have not been any better curative or effective disease-modifying therapies for the treatment of Alzheimer's Disease (AD) for more than a decade. Despite millions of dollars spent on R&D and cost of care in AD, we still do not have a new treatment or combination therapy that can delay, stop, or reverse the progression of this neurodegenerative disease. It is estimated that delaying the onset of the disease by five years would decrease the no. of AD pts by 28-30% (2012 cost of care $172b!).

$2,000.00
Hepatitis C Virus Infection: Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next?  - Market Research Report

Hepatitis C Virus Infection: Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next?

Date Published: Apr 18 2012

HCV focused companies were in limelight last year with major launches, sales data and foremost astounding acquisition premium. The trend in volatility guided by surprises, disappointment is expected to continue this year too. Data presented at European Association for the Study of the Liver (EASL, April 18th - 22nd) this week will trigger the volatility and give food for thought- "was the premium paid justified"?

$2,000.00

Pages

Shopping cart

0 Items $0.00
Market Research Special Offers
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianB. Braun, Cobham, fiserv, Harris, Wipro, AonMunich Re, Lotte Chemical, National Post, First Data